Dear ,

In the current issue of the OncoWuXi Newsletter, we would like to share with you our update on KRAS G12C related in vivo tumor models. Other interesting topics covered in this issue include Luminex multiplex system and updates on HDACs related in vivo tumor models.

OncoWuXi Newsletter will continue to keep you up-to-date with our recent progress in cancer research. As part of WuXi Research Service Division (RSD), our topnotch Oncology-Immunology team is dedicated to providing end-to-end services and solutions to support the ever-changing research needs of cancer and autoimmune diseases and is your ideal partner for enabling technological breakthrough and accelerating cancer drug discovery.

Targeted Oncology
KRAS G12C Related In Vivo Tumor Models
(1)      KRAS background as a drug target
  • KRAS biology and role of KRAS mutation in cancer
  • KRASG12C inhibitors under development

(2)      KRAS G12C mutation related CDX models
  • AMG 510 3D CTG validation across 13 cancer cell lines with KRASG12C mutation
  • HCC44, NCI-H358, NCI-H2030, NCI-H2122, NCI-H23, and SW1573 lung cancer CDX models with KRASG12C mutation, validated with AMG 510 and ARS-1620
  • Mia-pa-ca 2 pancreatic cancer CDX model with KRASG12C mutation, validated with ARS-1620
  • SW1463 and SW837 colorectal cancer CDX models with KRASG12C mutation, validated with AMG 510
  • SW756 cervical cancer CDX model with KRASG12C mutation, validated with AMG 510

(3)      KRAS G12C mutation related PDX models
  • LU-01-0030, LU-01-0046, and LU-01-0462 lung cancer PDX models with KRASG12C mutation, validated with AMG 510
  • CO-04-0070, CO-04-0307, and CO-04-0315 colorectal cancer PDX models with KRASG12C mutation, validated with AMG 510


HDACs Related In Vivo Tumor Models

(1)    HDACs biology and background as a drug target

(2)    HDACs inhibitors and related CDX models
  • MM.1S, RPMI-8226, NCI-H929 multiple myeloma CDX models, validated with ACY-1215, Ixazomib, ACY-241 and Pomalidomide
  • Mino lymphoma CDX model, validated with ACY-1215 and Ibrutinib
  • MV4-11 leukemia CDX model, validated with ACY-1215 and Panobinostat
  • MDA-MB-231 breast cancer CDX model, validated with Romidepsin
Pharmacodynamics Capabilities
Application of Luminex Multiplex System
(1)    Detection principle

(2)    Bio-Plex cytokine assay workflow

(3)    Advantages of Luminex multiplex system

(4)    Sample types and applications

(5) Case study of examination of IL-6, IL-23 and TNF-α
production in C57BL/6 plasma after different treatment

We sincerely appreciate your interest, time and support, and would like to hear your feedback so we can continuously improve our service. Please don't hesitate to email us if you have any questions, suggestions or concerns.

 
Best regards,
WuXi AppTec OncoWuXi Team